Celularity, Inc. (NASDAQ:CELU) Sees Large Decrease in Short Interest

Celularity, Inc. (NASDAQ:CELU) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totaling 294,642 shares, a decline of 32.0% from the March 15th total of 433,481 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 45,928 shares, the short-interest ratio is presently 6.4 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CELU. Vanguard Group Inc. lifted its position in Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares in the last quarter. Yorkville Advisors Global LP acquired a new position in Celularity during the third quarter valued at approximately $207,000. Jane Street Group LLC acquired a new position in Celularity during the fourth quarter valued at approximately $46,000. HB Wealth Management LLC acquired a new position in Celularity during the third quarter valued at approximately $84,000. Finally, Bank of America Corp DE lifted its position in Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares in the last quarter. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Stock Up 0.8%

Shares of CELU stock opened at $1.28 on Tuesday. The stock has a market cap of $36.92 million, a price-to-earnings ratio of -0.38 and a beta of 0.70. Celularity has a fifty-two week low of $1.01 and a fifty-two week high of $4.35. The firm’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.53.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.